There are 2789 resources available
203P - Randomized study of single-agent metronomic versus weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with HR+/HER2- advanced breast cancer
Presenter: Marina Cazzaniga
Session: ePoster Display
204P - Predictive factors for relapse in triple-negative breast cancer (TNBC) patients without pathologic complete response (PCR)
Presenter: Marta Venturelli
Session: ePoster Display
205P - Immunomodulation in early triple-negative breast cancer (TNBC): Analysis of soluble markers as predictive biomarkers to neoadjuvant chemotherapy in TNBC
Presenter: Martin Nunez Abad
Session: ePoster Display
206P - Disease behavior and treatment response of special histological types of triple-negative breast cancer
Presenter: Renata Bonadio
Session: ePoster Display
207P - Outcomes of patients with triple-negative breast cancer following neoadjuvant chemotherapy with anthracycline and taxane-based regimens plus carboplatin
Presenter: Bryan Vaca Cartagena
Session: ePoster Display
208P - ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC
Presenter: Peter Schmid
Session: ePoster Display
209P - Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors
Presenter: Samuel Klempner
Session: ePoster Display
210P - TACH101, a first-in-class KDM4 inhibitor for treatment of triple-negative breast cancer
Presenter: Frank Perabo
Session: ePoster Display
211P - Genetic and immunologic characteristics in Chinese breast patients with different HER2 mutation types
Presenter: Hui Cao
Session: ePoster Display
284P - Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study
Presenter: Seock-Ah Im
Session: ePoster Display